Waters buys MOBILion to push into the $2 billion LC-MS proteomics market

These two pieces of news land on different desks. The quarter is about the routine lab: the QC bench testing GLP-1 drugs, or the environmental lab adding trace-level PFAS capacity. The acquisition is about proteomics research and, much later, clinical blood testing. Buyers of mass spec capacity could hear both stories in the same sales meeting.

Sample volume behind the quarter

The existing Waters business accounted for $871 million, compared with $800 million in the same quarter a year before, a gain of 9% on a reported basis and 10% in constant currency. The remaining $896 million came from the Biosciences and Diagnostic Solutions businesses that Waters bought from Becton, Dickinson and Company.

The Analytical Sciences Division, home to Waters' liquid chromatography, mass spectrometry and chemistry products, brought in $703 million, up from $649 million. That is 8% growth as reported and 9% in constant currency. CEO Udit Batra named four factors driving LC-MS demand: labs replacing aging instruments, more testing tied to GLP-1 drugs, more PFAS analysis, and growth in generic drug production in India.

Every driver Batra named is a reason to run more samples, and samples are what use up columns and sample prep kits. An instrument is a one-time purchase. Chemistry is bought again with every batch. For labs where GLP-1 characterization or PFAS methods are scaling up, the quarter suggests that per-sample consumable costs belong in any platform comparison, next to the instrument quote.

Most of the smaller lines grew as well. The Materials Sciences Division, formerly TA Instruments, climbed to $93 million from $87 million. The Biosciences Division, formerly BD Biosciences, reported $396 million, and its research reagents and clinical reagents each grew at a high single-digit rate. Diagnostic Solutions, part of the Advanced Diagnostics Division, generated $500 million. The Clinical Business Unit, whose customers are clinical mass spectrometry labs and other diagnostic labs, increased to $75 million from $64 million. That line is important for the acquisition, as explained below.

A second separation step inside the mass spec

Liquid chromatography separates a sample over minutes as it moves through a column. SLIM, short for structures for lossless ion manipulations, adds a gas-phase separation after that, in milliseconds. LCGC International described it as a high-resolution separation step that complements liquid chromatography, which is why chromatographers are likely to pay attention.

The more practical detail is the workflow Waters described from discovery to development. Discovery runs on the Xevo MRT with SLIM. Targeted verification and validation of biomarker candidates in clinical trial cohorts move to the Xevo TQ Absolute XR tandem quadrupole. Workflows in the waters_connect platform support method transfer from discovery into development. For translational labs that now hand off discovery results to a separate targeted-assay group on different software, a single vendor path is the part of the pitch to test in a demo.

Waters sizes LC-MS proteomics at $2 billion, growing at a high single-digit rate. That estimate comes from the company's internal analysis, drawing on consulting data and market research. Financial terms of the deal were not disclosed.

When an AI agent runs the instrument

The argument is about volume. Foundation and frontier AI models need large amounts of high-quality data, and large cohort proteomics studies are limited by how many samples a lab can run and how deeply each run covers the proteome. Waters is pitching SLIM as the throughput piece of that system and MCP as the control layer. For directors of proteomics core facilities and the IT leaders who support them, this suggests that how agents connect to instruments is becoming something to compare between vendors, alongside resolution and uptime.

There is a fair objection to all of this. The quarter's growth came from regulated, routine testing, and the clinical uses Waters describes, multi-cancer early detection (MCED) and minimal residual disease (MRD) monitoring, are presented as long-term goals, not products. Waters ties that path to its installed base of mass spectrometers in clinical labs, the business behind the $75 million Clinical Business Unit line. For now, MOBILion is a research-lab bet.

Raised guidance and the 2027 drivers

The company now projects organic growth in constant currency of 9.1% to 9.7%. It expects total reported revenue between $6.479 billion and $6.497 billion, raising the midpoint by $43 million. Batra said the acquired businesses are being integrated faster than planned. For the fourth quarter, guidance calls for double-digit growth on a days-adjusted basis in both the existing and the acquired businesses.

Management also planned to set out a starting framework for 2027 on its earnings call, covering how reshoring, integration cost savings and AI-related demand would shape growth. The signal to watch is that third item. If AI-related demand shows up next year as a named growth driver alongside GLP-1 and PFAS, the MOBILion deal will be contributing to revenue sooner than its clinical roadmap suggests.